Treatment(s) already received-Biological/Targeted therapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Biological/Targeted therapy Posts on Medivizor

Searching for patients with relapsed or unresponsive small lymphocytic lymphoma to test an immune cell-stimulating treatment

Posted by on Dec 19, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells.  The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH, the...

Read More

Searching for patients to try a new therapy for non-responsive multiple myeloma.

Posted by on Feb 23, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial will investigate the effects of bb2121 in patients with non-responsive multiple myeloma (MM) who have progressed after standard treatment. The percentage of patients who respond and the percentage of patients who respond completely will be the main measures in this study. This study will take place in the United States and...

Read More

Searching for patients to test a new treatment for unresponsive multiple myeloma.

Posted by on Feb 9, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial is comparing the effectiveness of a new therapy, bb2121, to commonly used combinations of drugs for relapsing/refractory (unresponsive) multiple myeloma (RRMM). The main outcome to be measured is the time from the start of treatment until cancer worsens. The details Many patients are cured with standard treatments, such as...

Read More

Evaluating the use of PET scanning after first-line treatment for follicular lymphoma

Posted by on Nov 14, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the value of PET (positron emission tomography) scanning after first-line (primary) chemoimmunotherapy in patients with previously untreated follicular lymphoma (FL). This study concluded that PET scanning is a better imaging technique than CT (computed tomography) for assessing treatment response in these...

Read More

Evaluating rituximab maintenance therapy in patients with newly diagnosed follicular lymphoma

Posted by on Sep 6, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy in patients with newly diagnosed follicular lymphoma (FL). This study concluded that this therapy improves survival outcomes in these patients. Some background For patients with early (stage 1 – 2) FL, aggressive radiotherapy or...

Read More

Evaluating the impact of omitting vincristine on the outcomes of patients with DLBCL

Posted by on Aug 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated whether the omission of vincristine (Oncovin) from the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen affects survival in patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that omitting vincristine does not affect survival in these patients. Some background...

Read More

Is coltuximab ravtansine safe and effective for persistent diffuse large B-cell lymphoma?

Posted by on Jun 29, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of coltuximab ravtansine for relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. The authors concluded that coltuximab ravtansine monotherapy was reasonably effective and well-tolerated in these patients. Some background The most widely used treatment...

Read More

Carfilzomib – once weekly or twice weekly to treat unresponsive multiple myeloma?

Posted by on Jun 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT in mantle cell lymphoma?

Posted by on May 31, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with mantle cell lymphoma (MCL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of care for...

Read More